Lunai Bioworks Inc. (LNAI) is a Healthcare stock trading at $2.16 (as of 2026-08-21), with a market capitalization of $78.35M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Understand Lunai Bioworks Inc.: how it makes money
Lunai Bioworks Inc. is a healthcare company focused on pharmaceutical products. The provided facts do not specify how it makes money (for example, product sales, licensing, or services).
The company reports a gross margin of 100%, but an operating margin of -7054%, implying operating expenses overwhelm gross profit.
Business quality (Unprofitable): Unprofitable
Bull case
Gross profit looks intact: The company reports a gross margin 100%, which suggests it can generate gross profit on its costs. If operating expenses come under control, that gross profitability could matter for eventual earnings power.
Bear case
Operating losses are extreme: The company reports an operating margin -7054%, which indicates operating expenses are far exceeding gross profit. This level of loss makes near term profitability difficult and increases the risk of continued cash burn.
Valuation — source: SEC EDGAR (first-party)
Price
$2.16
Market Cap
$78.35M
FCF Yield
-7.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)
$122041.00
Net Margin
-92947.0%
Valuation vs Sector & Industry
Sector P/E (Healthcare)
21.7
Industry P/E (Pharmaceutical Products)
17.0
Company
Sector
Healthcare
Industry
Pharmaceutical Products
Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)